NovoCure Ltd. (NVCR)
NASDAQ
14.68
-0.42 (-2.78%)
Closed
Oct 23, 2026
Day's Range
14.5314.97
52 wk Range
9.8221.45
Financial Statements - NVCR - NovoCure Ltd.
Revenue
655.35M▲ 8.3%
Net Income
-136.22M▲ 19.2%Net Margin -20.8%
EBITDA
-100.24M▲ 7.9%
Free Cash Flow
-75.67M▼ 9.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 655.35M | 605.22M | 509.33M | 537.84M | 535.03M | 494.36M |
| Cost of Goods | 166.87M | 137.18M | 128.28M | 114.86M | 114.87M | 106.50M |
| Gross Profit | 488.47M | 468.03M | 381.05M | 422.97M | 420.15M | 387.86M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -153.80M | -170.49M | -232.87M | -89.52M | -44.33M | 30.40M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -4.32M | -717K | -797K | -3.52M | -4.03M | 2.64M |
| Pre Tax Income | -136.25M | -131.16M | -191.74M | -81.84M | -52.07M | 18.10M |
| Income Tax | -23K | 37.46M | 15.30M | 10.68M | 6.27M | -1.70M |
| Net Income | -136.22M | -168.62M | -207.04M | -92.53M | -58.35M | 19.80M |
| EPS Basic | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.2 |
| EPS Diluted | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.18 |
| Basic Shares Outstanding | 111.47M | 107.83M | 106.39M | 104.66M | 103.43M | 100.93M |
| Diluted Shares Outstanding | 111.47M | 107.83M | 106.39M | 104.66M | 103.43M | 100.93M |
| Ebit | -119.21M | -120.81M | -188.42M | -78.51M | -48.63M | 35.68M |
| Ebitda | -100.24M | -108.86M | -176.65M | -64.36M | -34.35M | 42.18M |
| Net Income Continuous Operations | -136.22M | -168.62M | -207.04M | -92.53M | -58.35M | 19.80M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
